Allergan Director Chris Bodline purchased 3,030 shares of company stock Dec. 7, The Ledger Gazette reports.
Here's four insights into Allergan:
1. Mr. Bodine purchased the shares at an average cost of $164.77 per share, for a total of $499,253.
2. Allergan has a 52-week high of $256.80 and a 52-week low of $160.07.
3. The company hit $163.58 Jan. 1.
4. CNBC analyst Jim Cramer criticized the company's stock saying it "can't catch a break." Mr. Cramer said Allergan is facing "endless competition," with no immediate path to create separation," the Kaplan Herald reports.
Mr. Cramer compared Allergan to the booming cryptocurrency Bitcoin saying the drug maker is the "anti-bitcoin," concerning gained value. Mr. Cramer believes Allergan's stock has no immediate pathway to achieve increased value.